- Home
- RCKY vs MOLN Comparison
RCKY vs MOLN Comparison
Compare RCKY & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- MOLN
- Stock Information
- Founded
- RCKY 1932
- MOLN 2004
- Country
- RCKY United States
- MOLN Switzerland
- Employees
- RCKY 2100
- MOLN N/A
- Industry
- RCKY Shoe Manufacturing
- MOLN
- Sector
- RCKY Consumer Discretionary
- MOLN
- Exchange
- RCKY Nasdaq
- MOLN Nasdaq
- Market Cap
- RCKY 170.2M
- MOLN 195.4M
- IPO Year
- RCKY 1993
- MOLN 2021
- Fundamental
- Price
- RCKY $22.87
- MOLN $5.19
- Analyst Decision
- RCKY Hold
- MOLN
- Analyst Count
- RCKY 2
- MOLN 0
- Target Price
- RCKY $24.50
- MOLN N/A
- AVG Volume (30 Days)
- RCKY 43.0K
- MOLN 25.4K
- Earning Date
- RCKY 10-30-2024
- MOLN 08-26-2024
- Dividend Yield
- RCKY 2.71%
- MOLN N/A
- EPS Growth
- RCKY 28.46
- MOLN N/A
- EPS
- RCKY 1.78
- MOLN N/A
- Revenue
- RCKY $451,670,000.00
- MOLN $7,105,397.00
- Revenue This Year
- RCKY N/A
- MOLN N/A
- Revenue Next Year
- RCKY $3.97
- MOLN $29.41
- P/E Ratio
- RCKY $12.81
- MOLN N/A
- Revenue Growth
- RCKY N/A
- MOLN N/A
- 52 Week Low
- RCKY $19.65
- MOLN $3.32
- 52 Week High
- RCKY $40.14
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- RCKY 47.06
- MOLN 42.35
- Support Level
- RCKY $21.79
- MOLN $5.25
- Resistance Level
- RCKY $24.67
- MOLN $5.46
- Average True Range (ATR)
- RCKY 1.04
- MOLN 0.21
- MACD
- RCKY 0.15
- MOLN -0.04
- Stochastic Oscillator
- RCKY 32.59
- MOLN 6.67
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract. It generates majority of the revenue from Wholesale segment.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.